 1 Adjusted operating SIMPLIFY  22.2% reduction in general  profit and administrative spend In 2022 we have  $404m (2021: $362m) continued to make  good progress  1 Adjusted operating BUILD  Pricing Centre of Excellence pivoting the  profit margin (CoE) delivered improvement   Embedded Pricing, Sales and  business to  Marketing CoEs 19.5% sustainable and  (2021: 17.7%) profitable growth Basic earnings per share EXECUTE Read more in our Chief Executives   13% reduction in complaints  review on pages 14 to 19 per million 3.1  Manufacturing productivity  improvements (2021: 5.9) 1 Read more about our  Adjusted basic earnings  progress on our FISBE  per share strategy on pages 14 to 19 We also made considerable  12.7 progress embedding our  (2021: 13.1) ESG framework, Convatec  Cares. See pages 40 to 74 1. Certain financial measures in this Annual Report and Accounts, including  adjusted performance measures above, are not prepared in accordance  with IFRS. All adjusted performance measures are reconciled to the most  directly comparable measure prepared in accordance with IFRS on pages  224 to 228. 2. In constant currency. Convatec Group Plc Annual Report and Accounts 2022 1 Overview Convatec at a glance About us Convatec is a global  THE SCALE OF OUR BUSINESS medical solutions and  technologies company,  Group-reported revenue Group-reported revenue  committed to the people  by category by geography we serve patients living  with chronic conditions,  their care givers and the  $2,073m $2,073m healthcare professionals  who support them.  Since 1964 we have  supported patients   A dvanced Wound Care: 30% $621m Europe: 33% $689m in managing long-term Ostomy Care: 25% $522m North America: 53% $1,090m  C ontinence & Critical Care: 26% $546m Rest of world: 14% $294m conditions, with leading   I nfusion Care: 19% $384m market positions in  Advanced Wound Care,  KEY FACTS Ostomy Care, Continence  and Critical Care  ~850m 12 and Infusion Care. finished products key markets ~10,000 9 colleagues manufacturing locations OUR PROMISE: FOREVER CARING OUR VALUES Improve 14 Convatec Group Plc Annual Report and Accounts 2022 Overview Strategic report Governance Financial statements Additional information our production facilities and developing  We delivered a strong financial  new digital technologies to deliver  performance  Focus enhanced customer experiences. We  Group reported revenue of $2,073  were able to accelerate our plans,  million rose 1.7% (2021: $2,038 million).  making good progress on several  We further reshaped the business to  Adjusting for the significant FX  significant projects, notably the  focus on our four chronic care categories  headwind, revenue grew 6.9% on a  expansion of capacity in Osted and  through bolt-on acquisitions, notably  constant currency basis and 5.6% on  Reynosa for our Infusion Care business,  the Triad Life Sciences acquisition which  an organic basis, slightly ahead of our  and beginning to increase automation  gives us a foothold in the important  initial guidance.  at our Deeside wound care facility. We  wound biologics segment. This, coupled  also invested in acquiring intellectual  with the withdrawal from non-core  Adjusted operating profit rose 11.6%  property for our Ostomy Care  hospital care activities and related  and 12.2% on a constant currency basis  accessories portfolio. industrial sales, means that over 90% of  despite significant COGS inflation of  our revenue now comes from chronic  8.6%. Adjusted operating profit margin  Cash conversion was 55.6% (2021: 73.0%)  care markets.  was 19.5% (2021: 17.7%) with mix / price,  primarily reflecting increased capital  operations productivity, significant G&A  expenditure and the strategic decision  We continued to focus and invest in our  spend reduction and 80bps of foreign  to build inventory for resilience, coupled  12 key markets which cumulatively  exchange tailwind more than offsetting  with the timing of receivables. We  delivered constant currency revenue  significant inflation and continued  expect phasing of some receivables to  growth of 9.6%, ahead of the overall  investment in commercial capabilities. reverse in H1 2023 112 Convatec Group Plc Annual Report and Accounts 2022 Overview Strategic report Governance Financial statements Additional information 1 Dr Divakar Ramakrishnan Bruno Pinheiro Evelyn Douglas  Executive Vice President, Chief President & Chief Operating Officer, Executive Vice President, Chief  Technology Officer & Head of Ostomy Care Corporate Strategy and Business  Research & Development Development, General Counsel  & Company Secretary Appointed to CELT: 2020 Appointed to CELT: 2021 Appointed to CELT: 2020 Prior to joining Convatec three years Bruno worked for Bristol Myers Squibb Evy has in-depth expertise in the  ago, Divakar served as Chief Digital prior to its sale to Convatec in April MedTech sector, having spent 20  Officer and Vice President for Eli Lillys 2005. Brunos diverse experience years at Becton, Dickinson and  Drug Delivery, Device and Digital Health spans across Sales, Business Company (BD) prior to joining  groups, where he led a global R&D team Development & Global Emerging Convatec in 2020. At BD, she was  focused on developing innovative and Markets. Prior to his appointment as Senior Vice President of Corporate  digitally-enabled devices to improve interim President & COO, Global Development and Strategy, where  patient care. Divakars career in Emerging Markets, Bruno led a diverse she supported the company to  healthcare spans more than 20 years. team across eight countries in his role build its capabilities, focusing on  He served as Eli Lillys Vice President of as Head of Convatecs Latin America opportunities for partnerships,  Manufacturing Science and Technology, business. Bruno was appointed as acquisitions and divestitures. Prior  a role in which he oversaw all the President & Chief Operating Officer, to her role in corporate development  companys process development